SVNS — Solvonis Therapeutics Share News
0.000.00%
Solvonis Therapeutic - Synthesis of development candidate for SVN-SDN-014
Solvonis Therapeutic - Notice of Annual General Meeting
Solvonis Therapeutic - Appointment of Prof. David Nutt as CSO
Solvonis Therapeutic - Holding(s) in Company
Solvonis Therapeutic - Holding(s) in Company
Solvonis Therapeutic - Holding(s) in Company
Solvonis Therapeutic - Holding(s) in Company
RCS - Solvonis Therapeutic - Presentation at Mello2025
Solvonis Therapeutic - Holding(s) in Company
Solvonis Therapeutic - Completion of the acquisition of Awakn
Solvonis Therapeutic - Result of placing
Solvonis Therapeutic - Proposed equity fundraising via ABB
Brief: Solvonis Therapeutics Security Holders Of Awakn Life Sciences Approved Proposed Acquisition Of Awakn By Solvonis
Solvonis Therapeutic - Proposed acquisition of Awakn approved
Solvonis Therapeutic - Final Results for the year ended 31 December 2024
Solvonis Therapeutic - Posting of Circular and Notice of General Meeting
Solvonis Therapeutic - Holding(s) in Company
Brief: Solvonis Therapeutics Says Engaged with Pharmaventures To Support Commercialisation Of Two Clinical-Stage Programmes
Solvonis Therapeutic - Engagement of PharmaVentures